Rule 13: Why Your Active Device Might Be Class IIb

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

Rule 13 is one of the most misunderstood classification rules under MDR Annex VIII. Unlike Rules 9 through 12, which categorize by anatomical location or invasiveness, Rule 13 focuses on function and biological impact.

The rule seems straightforward on paper. In practice, manufacturers regularly underestimate its scope. They read “administer or exchange energy” and assume this means high-power devices. They see “biological effect” and think this excludes devices with gentle or gradual action.

Both assumptions lead to incorrect classification. And incorrect classification means submission delays, regulatory gaps, and clinical evaluation reports that don’t match the device’s actual risk profile.

What Rule 13 Actually Says

Rule 13 classifies all active therapeutic devices intended to administer or exchange energy with the human body in a potentially hazardous way as Class IIb. The exception: devices whose performance characteristics are specifically designed to enable monitoring of the administration of energy. Those fall to Class IIa.

The key term here is “potentially hazardous way.” This doesn’t mean the device must cause harm. It means the manner in which energy is delivered could, under certain conditions, present risk.

MDCG 2021-24 clarifies that “potentially hazardous” should be interpreted in relation to the nature of the energy, the mode of application, and the intended biological effect. If the device’s mechanism involves a biological response triggered by energy delivery, the classification question shifts from “how much energy” to “what does this energy do.”

Where Manufacturers Go Wrong

The most common mistake is comparing energy output to arbitrary thresholds. A manufacturer looks at their device and sees modest wattage, gentle heating, or short exposure times. They conclude: not hazardous.

But hazard isn’t just about magnitude. It’s about controllability and biological interaction.

Take a transcutaneous electrical nerve stimulation device. Low voltage, low current, applied externally. A manufacturer might classify it as Class IIa, reasoning that the energy levels are minimal. But if the device is intended to produce a therapeutic effect by altering nerve activity, that’s a biological interaction mediated by energy. Rule 13 applies.

Or consider a light therapy device for dermatological treatment. LED-based, non-ablative, superficial application. The manufacturer sees no cutting, no deep penetration, no thermal injury. But the intended effect is photobiomodulation: a cellular response triggered by specific wavelengths. Energy is exchanged with tissue in a way that produces a biological effect. Rule 13 applies again.

The Monitoring Exception

Rule 13 includes an exception: devices whose performance characteristics are specifically designed to monitor energy administration can remain Class IIa.

This exception is narrower than it appears.

The key word is “specifically designed.” It’s not enough that the device includes some feedback mechanism or display. The monitoring function must be integral to the device’s safety profile and must actively enable control of the energy delivery process.

A pulse oximeter used during surgical energy delivery would qualify. Its entire purpose is to provide real-time information that guides safe energy application.

But a heating pad with a temperature readout doesn’t qualify. The readout is informational. It doesn’t enable real-time control of the biological interaction. The device still administers thermal energy with potential for tissue effect. Class IIb applies.

Notified Bodies scrutinize this exception carefully. If the manufacturer claims Class IIa under the monitoring provision, they expect to see design documentation, risk analysis, and clinical evidence demonstrating how the monitoring function actively mitigates the hazard of energy delivery.

Why This Matters for Clinical Evaluation

Classification isn’t just a regulatory checkbox. It determines the depth of clinical evidence required and the scrutiny applied by Notified Bodies and regulators.

A Class IIa device may rely more heavily on literature and equivalence arguments, especially if the risk profile is well understood and the clinical data landscape is mature.

A Class IIb device triggers stricter requirements. The clinical evaluation report must address the specific biological effects associated with energy delivery. It must demonstrate that the therapeutic claim is supported by evidence specific to the device’s mode of action.

When a manufacturer misclassifies a Rule 13 device as Class IIa, the clinical evaluation often reflects that error. The SOTA may focus on functional outcomes without adequately addressing energy-related risks. The equivalence analysis may compare devices based on indication without analyzing how energy parameters influence safety and performance.

Reviewers catch this quickly. They see a device that delivers energy to produce a biological effect, and they ask: where is the dose-response analysis? Where is the discussion of exposure limits? Where is the evidence that the chosen parameters are both effective and safe across the intended user population?

Real Scenarios That Trigger Rule 13

Let me give you examples I see repeatedly in submissions and audits.

Ultrasound physiotherapy devices. Low-intensity, non-ablative, used for pain relief or tissue healing. Manufacturers often assume Class IIa because there’s no surgical cutting. But the device administers acoustic energy to produce a biological effect in tissue. Rule 13 applies. Class IIb.

Radiofrequency aesthetic devices. Non-invasive skin tightening through controlled dermal heating. The energy levels are calibrated to avoid burns, but the therapeutic effect depends on collagen remodeling triggered by thermal energy. Rule 13 applies. Class IIb.

Neurostimulation devices. External or implanted, used for pain management or functional restoration. They deliver electrical pulses designed to modulate nerve activity. That’s energy administration with a direct biological effect. Rule 13 applies. Class IIb at minimum, often higher depending on invasiveness.

Phototherapy devices. Blue light for acne, red light for wound healing, infrared for circulation. The mechanism is photobiomodulation: light energy absorbed by cells triggers metabolic changes. Rule 13 applies. Class IIb.

In each case, the manufacturer might point to low power, external application, or non-invasive use. None of that changes the classification logic. If the device’s therapeutic claim depends on controlled energy delivery that produces a biological response, Rule 13 governs.

What Notified Bodies Look For

When reviewing a Rule 13 classification, Notified Bodies assess three things:

First: Does the device administer or exchange energy with the body? This includes electrical, thermal, acoustic, electromagnetic, and optical energy. It includes both delivery to tissue and extraction from tissue.

Second: Is the energy administration potentially hazardous? This is interpreted broadly. If incorrect energy parameters could lead to tissue damage, unintended physiological response, or compromised safety, it’s potentially hazardous.

Third: Does the device include monitoring features specifically designed to control that hazard? If yes, and if those features are integral to safe operation, the exception to Class IIa may apply. If no, Class IIb is appropriate.

They also cross-check the classification against the risk management file. If the risk analysis identifies energy delivery as a significant hazard source, but the device is classified as Class IIa, that’s a red flag. The classification and the risk analysis must align.

Implications for Your Technical File

If your device falls under Rule 13 and you’ve classified it as Class IIb, your technical documentation must reflect that classification throughout.

Your risk management file should include detailed analysis of energy-related hazards: parameter drift, user error in setting controls, variability in tissue response, cumulative exposure effects.

Your verification and validation protocols should include testing of energy output accuracy, stability over the device’s lifetime, and performance under boundary conditions.

Your clinical evaluation report should address how the chosen energy parameters were determined, what evidence supports their safety and efficacy, and how the device’s performance compares to other energy-based therapies in the same clinical domain.

Your instructions for use must clearly explain the relationship between energy settings and clinical outcomes, and must provide guidance on avoiding harmful exposure.

All of this is standard for a well-documented Class IIb device. But if your initial classification was incorrect, these elements may be incomplete or absent. Correcting the classification mid-process means revisiting every section of the technical file.

How to Approach Classification Correctly

Start with the device’s intended purpose and mechanism of action. Ask: does this device deliver energy to the body to produce a therapeutic effect?

If the answer is yes, Rule 13 is in play. Don’t start with power levels or exposure duration. Start with whether energy delivery is central to the therapeutic claim.

Next, assess whether the energy delivery is potentially hazardous. Use MDCG 2021-24 as a guide. Consider not just extreme scenarios but also what happens if parameters are set incorrectly, if the device malfunctions, or if the patient’s tissue response differs from expected.

If the device includes monitoring or feedback features, evaluate whether those features are specifically designed to enable safe energy administration. Are they integral to the device’s safety architecture, or are they supplementary information displays?

Document your reasoning. Classification justification should be explicit, traceable, and aligned with MDCG guidance. If a Notified Body or competent authority questions your classification, you need to show the logic, not just the conclusion.

The Bigger Picture

Rule 13 reflects a principle that runs through the entire MDR classification system: risk is not just about where a device goes in the body, but what it does once it’s there.

Energy-based devices can be non-invasive, low-power, and user-friendly. They can also produce significant biological effects, both intended and unintended. The classification system accounts for that.

When manufacturers resist this logic, it’s often because they’re focused on market access timelines or comparative positioning against competitors. But incorrect classification doesn’t speed anything up. It creates deficiencies, delays, and rework.

The most efficient path is to classify correctly from the start, build the clinical and technical documentation to match, and submit a package that aligns across every section.

Rule 13 isn’t punitive. It’s a recognition that devices which act through energy delivery require a higher standard of evidence and control. If your device falls into that category, embrace the classification and build your submission accordingly.

Next in this series, I’ll cover Rule 11: devices incorporating a medicinal substance. Another area where intent and integration determine classification in ways manufacturers often misjudge.